ArticleEuropean radiology2018
Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.
Article in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review.Neuroradiology · 2021Pooled it
- Added diagnostic value of pseudocapsule and ADC heterogeneity beyond ccLS v2.0 in small renal masses.Abdominal radiology (New York) · 2026Article
- Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab.Journal of neuro-oncology · 2026Article
- Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives.Neuro-oncology · 2026Review
- Differentiation of Molecular Glioblastomas and Lower-grade Diffuse Astrocytomas Using MRI Perfusion and Diffusion Parameters.Clinical neuroradiology · 2026Article
- Impact of corticosteroid administration on contrast-enhancing volume and diffusion MRI in treatment naïve glioblastoma.Neuro-oncology · 2025Article
- Predictive markers for molecular subtypes and WHO grade: T1ρ-MRI in adult-type diffuse gliomas.Journal of neuro-oncology · 2025Article
- Automated Diffusion Analysis for Noninvasive Prediction ofAJNR. American journal of neuroradiology · 2025Article
- Advanced MRI, Radiomics and Radiogenomics in Unravelling Incidental Glioma Grading and Genetic Status: Where Are We?Medicina (Kaunas, Lithuania) · 2025Review
- Structured reporting of gliomas based on VASARI criteria to improve report content and consistency.BMC medical imaging · 2025Article
- Histogram analysis of diffusion weighted magnetic resonance imaging for predicting isocitrate dehydrogenase 1 mutation status in brain gliomas.Current journal of neurology · 2025Article
- Diffusion imaging in gliomas: how ADC values forecast glioma genetics.Polish journal of radiology · 2025Review
- Point-of-care mass spectrometry metabolomic analysis enabling intraoperative brain tumor diagnosis.Theranostics · 2025Article
- Diffusion MRI is superior to quantitative T2-FLAIR mismatch in predicting molecular subtypes of human non-enhancing gliomas.Neuroradiology · 2024Article
- Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma.Cancers · 2024Review
- Noninvasive prediction of BRAF V600E mutation status of pleomorphic xanthoastrocytomas with MRI morphologic features and diffusion-weighted imaging.BMC cancer · 2024Article
- Tumor-like Lesions in Primary Angiitis of the Central Nervous System: The Role of Magnetic Resonance Imaging in Differential Diagnosis.Diagnostics (Basel, Switzerland) · 2024Review
- Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET.Japanese journal of radiology · 2023Article
- Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.AJNR. American journal of neuroradiology · 2023Article
- A multi-reader comparison of normal-appearing white matter normalization techniques for perfusion and diffusion MRI in brain tumors.Neuroradiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesTo investigate if quantitative apparent diffusion coefficient (ADC) measurements can predict genetic subtypes of non-gadolinium-enhancing gliomas, comparing whole tumour against single slice analysis.
methodsVolumetric T2-derived masks of 44 gliomas were co-registered to ADC maps with ADC mean (ADC
resultsIsocitrate dehydrogenase (IDH) wild-type gliomas showed the lowest ADC values throughout (p < 0.001). ADC
conclusionsADC measurements can support the distinction of glioma subtypes. Volumetric and two-dimensional measurements yielded similar results in this study. KEY POINTS: • Diffusion-weighted MRI aids the identification of non-gadolinium-enhancing malignant gliomas • ADC measurements may permit non-gadolinium-enhancing glioma molecular subtyping • IDH wild-type gliomas have lower ADC values than IDH-mutant tumours • Single cross-section and volumetric ADC measurements yielded comparable results in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.